What new restricted share units did Brian Savage receive from Teva (TEVA)?

On March 4, 2026, he was granted 11,280 restricted share units. Each restricted share unit represents a contingent right to receive either one Teva ordinary share or, at the committee’s option, the cash value of one ordinary share at settlement, subject to vesting terms.

How are Teva (TEVA) restricted share units structured for Brian Savage?

Each restricted share unit represents a contingent right to receive, upon settlement, one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. Specific vesting schedules are detailed for grants made in 2022, 2024, and 2026.

Teva (TEVA) interim CLO acquires RSUs and sells 2,675 shares for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.

On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.

Insider Trade Summary

Net Seller: 2,675 shares ($86,843)

Net Sell 7 txns

Insider Savage Brian

Role Interim Chief Legal Officer

Sold 2,675 shs ($87K)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	4,744	$0.00	--
Exercise	Restricted Share Units	3,766	$0.00	--
Grant/Award	Restricted Share Units	11,280	$0.00	--
Exercise	Ordinary Shares	4,744	$0.00	--
Sale	Ordinary Shares	1,489	$32.4645	$48K
Exercise	Ordinary Shares	3,466	$0.00	--
Sale	Ordinary Shares	1,186	$32.4645	$39K

Holdings After Transaction: Restricted Share Units — 0 shares (Direct); Ordinary Shares — 7,670 shares (Direct)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026. Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028. Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

Form 4 Insider Transactions: What Each Field Means →

03/06/2026 - 04:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage Brian

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV

6944020

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	03/04/2026		M		4,744	A	⁽²⁾	7,670	D
Ordinary Shares⁽¹⁾	03/04/2026		S		1,489⁽³⁾	D	$32.4645⁽⁴⁾	6,181	D
Ordinary Shares⁽¹⁾	03/04/2026		M		3,466	A	⁽²⁾	9,647	D
Ordinary Shares⁽¹⁾	03/04/2026		S		1,186⁽³⁾	D	$32.4645⁽⁴⁾	8,461	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽²⁾	03/04/2026		M			4,744	⁽⁵⁾	⁽⁵⁾	Ordinary Shares⁽¹⁾	4,744	$0	0	D
Restricted Share Units	⁽²⁾	03/04/2026		M			3,766	⁽⁶⁾	⁽⁶⁾	Ordinary Shares⁽¹⁾	3,766	$0	7,534	D
Restricted Share Units	⁽²⁾	03/04/2026		A		11,280		⁽⁷⁾	⁽⁷⁾	Ordinary Shares⁽¹⁾	11,280	$0	11,280	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026.

6. Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028.

7. Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Brian Savage report in Teva (TEVA) shares?

Brian Savage reported multiple equity compensation transactions, including exercises of restricted share units into ordinary shares, a new grant of 11,280 restricted share units, and open-market sales of 2,675 ordinary shares primarily to cover tax withholding obligations related to vesting awards.

How many Teva (TEVA) shares did Brian Savage sell on March 4, 2026?

He sold a total of 2,675 Teva ordinary shares on March 4, 2026, split between 1,489 shares and 1,186 shares. The weighted average sale price reported was $32.4645 per share across multiple transactions within a disclosed price range.

Why were some of Brian Savage’s Teva (TEVA) shares sold in this Form 4 filing?

The filing states the 2,675 Teva ordinary shares sold represented the number of shares required to be sold to cover tax withholding obligations. These obligations arose in connection with the vesting of restricted share units reported in the derivative securities table.

How many Teva (TEVA) shares does Brian Savage own after these transactions?

Following the reported transactions on March 4, 2026, Brian Savage directly owned 8,461 Teva ordinary shares. This figure reflects the combined effect of restricted share unit exercises that increased his holdings and the share sales executed to satisfy tax withholding requirements.